Not So Different: A Podcast from The Center for Biosimilars

Show notes: To read more about Amgen’s Biosimilar Trends Report, click here . To learn more about the Inflation Reduction Act’s impact on biosimilars, click here . To see more of Chad’s takeaways from older version of Amgen’s Biosimilar Trends Report, click here . To learn more about tender systems, click here . To check out the last episode of Not So Different, click here .

This episode is made in conjunction with the third annual Global Biosimilars Week, a biosimilar awareness campaign hosted by the International Generic and Biosimilar Association (IGBA) from November 14 through November 18. The Center for Biosimilars is a proud media partner for Global Biosimilars Week and you can check all our social media pages to view our coverage of the event. To learn more abo...

Show notes Saskatchewan Becomes Sixth Canadian Province to Implement a Biosimilar Switching Policy Advocacy Organization Calls for Ontario to Switch Patients to Biosimilars BioRationality: a Dr Sarfaraz Niazi Column—The EMA Declares Biosimilars Interchangeable Biden Authorizes Update to the Biosimilar User Fee Act Through 2027 New Bill Aims to Remove Barriers to Interchangeable Biosimilars Amgen R...

Show notes:  To read more of Kathy’s thoughts on the practice perspective regarding biosimilars, click here . To learn more about automatic substitution policies, click here .  To learn more about some of the challenges clinicians could face next year as adalimumab biosimilars enter the market, click here . To learn more about prescription behaviors regarding biosimilars, click here . To listen to...

Show notes FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar https://www.centerforbiosimilars.com/view/fda-approves-stimufend-the-us-sixth-pegfilgrastim-biosimilar   FDA Approves Celltrion Biosimilar for Avastin, Vegzelma https://www.centerforbiosimilars.com/view/fda-approves-celltrion-biosimilar-for-avastin-vegzelma Oncology, Ophthalmology Biosimilars Progress in Europe https://www.c...

This special episode is part of a larger series called “WHEN CHOICE ARRIVES: Competition & Consequences,” consisting of 4 articles and 2 podcasts. The series delves into everything that stakeholders need to know as everyone prepares for the 2023 introduction of adalimumab biosimilars. To read part 1 of this series, “Biosimilars to Bring a Bumper Crop of Adalimumab Options,” click here . To rea...

This special episode is part of a larger series called “WHEN CHOICE ARRIVES: Competition & Consequences,” consisting of 4 articles and 2 podcasts. The series delves into everything that stakeholders need to know as everyone prepares for the 2023 introduction of adalimumab biosimilars. To read part 1 of this series, “Biosimilars to Bring a Bumper Crop of Adalimumab Options,” click here . To rea...

Opinion: Impact of Inflation Reduction Act 2022—Addressing Critics https://www.centerforbiosimilars.com/view/opinion-impact-of-inflation-reduction-act-2022-addressing-critics Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar Competition https://www.centerforbiosimilars.com/view/opinion-the-inflation-reduction-act-is-a-step-backward-for-biosimilar-competition $35 Insulin Cap fo...

Show notes: To learn more about McKesson’s Intrafusion, click here . To learn more about biosimilar storage concerns, click here .

Show notes Written version of the roundup Phase 3 denosumab trial results Alvotech’s pharmacokinetics trial for denosumab Poster from the American Society of Clinical Oncology’s annual meeting Phase 1 pertuzumab trial Rituximab studies from the European Hematology Association Congress 2022 Survey on preparing patients and providers for switching to a biosimilar

To learn more about the hype regarding adalimumab biosimilars in the US, click here . To see which biosimilars have been approved by the FDA, click here . To read more on PBMs and their influence on biosimilar uptake, click here . To read Manolis’ 2016 paper, click here .

Show notes: To learn more about the US launch of Byooviz, click here . To read more about the anticipation for ophthalmology biosimilars, click here . To read more of Dr. Oskouei’s comments on “Round 2,” click here . To learn more about the EU approval of Byooviz, click here . To learn more about the Canadian approval of Byooviz, click here . To read more on the anticipation for aflibercept biosim...

To listen to part 1 of this podcast, click here . To listen to part 2 of this podcast, click here . To learn more about building patient confidence in biosimilars, click here . To learn more about how education can improve patient confidence, click here .

To listen to part 1 of this podcast, click here . To learn more about building physician confidence in biosimilars, click here . For more on how switching to biosimilars can  impact budgets and savings, click here .

Despite some biosimilars, including those for filgrastim, trastuzumab, and bevacizumab, achieving a greater US market share than their originators, other biosimilar categories, such as pegfilgrastim and infliximab, are still trailing behind. Some biosimilar companies are becoming more savvy, developing new ways to make a bigger statement in the market. We sat down with Kirollos Hanna, PharmD, the...

A major barrier to biosimilar adoption is physician hesitancy when it comes to prescribing these agents, especially in the oncology space. Physicians often want more clinical or real-world evidence on the safety and efficacy of biosimilars compared with reference products in patients with cancer, for whom the stakes are high when choosing a therapeutic or supportive agent. Additionally, some clini...

To hear more from Paul on biosimilar issues, click here or here . To read about Paul’s insight on the current issues in the Indian biosimilar market, click here .

To learn more about the Hatch-Waxman Act, click here . To learn more about how biosimilars compare with the generics market, click here . To learn more about the challenges that both the biosimilars and generic markets face, click here .

For background reading on the ACA case, read about the June 2021 ruling here , and for background on the withdrawal of the Department of Justice from the plaintiffs’ side of the suit, click here . 

To hear more comments from Ping Cao, click here . To learn more about Henlius’ development plans, click here . To learn more about Henlius’ approval for their adalimumab biosimilar, click here . To learn more about PD-1 inhibitors, click here .

To learn more about Sonia’s work, click here . To learn more about pharmacists’ role in promoting biosimilars, click here .

To learn more about payer preferences, click here . To see how Minnesota legislators are working to override payer preferences, click here . For more on payer influence on prescribing patterns, click here . For more on NCCN’s biosimilar work, click here .   You can also check out part 1 and part 2 of this series. To check out our Biosimilar Approvals navigator, click here .

To learn more about struggles regarding physician decisions on biosimilars, click here . For more on payer influence on prescribing patterns, click here . For more on NCCN’s biosimilar work, click here .

For more on biosimilar perception, click here .  For more on NCCN’s biosimilar work, click here .

To learn more about Brexit's impact on the biologics industry, click here .